{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.4","upperLimit":"62.9","value":"49.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). The percentage of participants who experienced CR or PR as assessed by blinded independent central review (BICR) were presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 Q3W IV for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to ~34 months","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}